Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 518284, 12 pages
http://dx.doi.org/10.1155/2015/518284
Research Article

Prognosis Relevance of Serum Cytokines in Pancreatic Cancer

1Department of Biochemistry and Molecular Biology I, University of Granada, 18071 Granada, Spain
2Department of Health Sciences, University of Jaen, 23071 Jaen, Spain
3Department of Human Anatomy and Embryology, University of Granada, 18012 Granada, Spain
4Oncology Service, Virgen de las Nieves Hospital, 18014 Granada, Spain
5Department of Computer Architecture and Computer Technology (CITIC-UGR), University of Granada, 18071 Granada, Spain

Received 4 November 2014; Revised 5 January 2015; Accepted 12 January 2015

Academic Editor: Wen-Bin Wu

Copyright © 2015 Carolina Torres et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2012,” CA: Cancer Journal for Clinicians, vol. 62, no. 1, pp. 10–29, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Samuel and T. J. Hudson, “The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma,” Nature Reviews Gastroenterology and Hepatology, vol. 9, no. 2, pp. 77–87, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Zieger, “High throughput molecular diagnostics in bladder cancer—on the brink of clinical utility,” Molecular Oncology, vol. 1, no. 4, pp. 384–394, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Hidalgo and D. D. Von Hoff, “Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas,” Clinical Cancer Research, vol. 18, no. 16, pp. 4249–4256, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Costello, W. Greenhalf, and J. P. Neoptolemos, “New biomarkers and targets in pancreatic cancer and their application to treatment,” Nature Reviews Gastroenterology and Hepatology, vol. 9, no. 8, pp. 435–444, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. A. J. Atkinson Jr., W. A. Colburn, V. G. DeGruttola et al., “Biomarkers and surrogate endpoints: preferred definitions and conceptual framework,” Clinical Pharmacology and Therapeutics, vol. 69, no. 3, pp. 89–95, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. J. M. Winter, C. J. Yeo, and J. R. Brody, “Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer,” Journal of Surgical Oncology, vol. 107, no. 1, pp. 15–22, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. G. M. Clark, “Prognostic factors versus predictive factors: examples from a clinical trial of erlotinib,” Molecular Oncology, vol. 1, no. 4, pp. 406–412, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. N. B. Jamieson, C. R. Carter, C. J. McKay, and K. A. Oien, “Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis,” Clinical Cancer Research, vol. 17, no. 10, pp. 3316–3331, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Garcea, C. P. Neal, C. J. Pattenden, W. P. Steward, and D. P. Berry, “Molecular prognostic markers in pancreatic cancer: a systematic review,” European Journal of Cancer, vol. 41, no. 15, pp. 2213–2236, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Luo, Z. Qiu, L. Tian et al., “Identification of novel predictive markers for the prognosis of pancreatic ductal adenocarcinoma,” Human Pathology, vol. 44, no. 1, pp. 69–76, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. C. D. Mann, C. Bastianpillai, C. P. Neal et al., “Notch3 and hey-1 as prognostic biomarkers in pancreatic adenocarcinoma,” PLoS ONE, vol. 7, no. 12, Article ID e51119, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Dallol, J. Al-Maghrabi, A. Buhmeida et al., “Methylation of the polycomb group target genes is a possible biomarker for favorable prognosis in colorectal cancer,” Cancer Epidemiology Biomarkers and Prevention, vol. 21, no. 11, pp. 2069–2075, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. S. M. Denley, N. B. Jamieson, P. McCall et al., “Activation of the IL-6R/Jak/stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma,” Journal of Gastrointestinal Surgery, vol. 17, no. 5, pp. 887–898, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Giovannetti, A. van der Velde, N. Funel et al., “High-throughput microRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancer,” PLoS ONE, vol. 7, no. 11, Article ID e49145, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. S. O. Dima, C. Tanase, R. Albulescu et al., “An exploratory study of inflammatory cytokines as prognostic biomarkers in patients with ductal pancreatic adenocarcinoma,” Pancreas, vol. 41, no. 7, pp. 1001–1007, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. A. J. Schetter, N. H. H. Heegaard, and C. C. Harris, “Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways,” Carcinogenesis, vol. 31, no. 1, pp. 37–49, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Germano, P. Allavena, and A. Mantovani, “Cytokines as a key component of cancer-related inflammation,” Cytokine, vol. 43, no. 3, pp. 374–379, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. X. Li, Q. Ma, Q. Xu, W. Duan, J. Lei, and E. Wu, “Targeting the cancer-stroma interaction: a potential approach for pancreatic cancer treatment,” Current Pharmaceutical Design, vol. 18, no. 17, pp. 2404–2415, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. M. V. Apte, S. Park, P. A. Phillips et al., “Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells,” Pancreas, vol. 29, no. 3, pp. 179–187, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. M. J. Moore, D. Goldstein, J. Hamm et al., “Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group,” Journal of Clinical Oncology, vol. 25, no. 15, pp. 1960–1966, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Kauffmann, R. Gentleman, and W. Huber, “arrayQualityMetrics—a bioconductor package for quality assessment of microarray data,” Bioinformatics, vol. 25, no. 3, pp. 415–416, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. E. L. Kaplan and P. Meier, “Nonparametric estimation from incomplete observations,” The Journal of the American Statistical Association, vol. 53, pp. 457–481, 1958. View at Publisher · View at Google Scholar · View at MathSciNet
  24. Y.-C. Hou, Y.-J. Chao, H.-L. Tung, H.-C. Wang, and Y.-S. Shan, “Coexpression of CD44-positive/CD133-positive cancer stem cells and CD204-positive tumor-associated macrophages is a predictor of survival in pancreatic ductal adenocarcinoma,” Cancer, vol. 120, no. 17, pp. 2766–2777, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Lemke, D. Schäfer, S. Sander, D. Henne-Bruns, and M. Kornmann, “Survival and prognostic factors in pancreatic and ampullary cancer,” Anticancer Research, vol. 34, no. 6, pp. 3011–3020, 2014. View at Google Scholar
  26. B. C. Özdemir, T. Pentcheva-Hoang, J. L. Carstens et al., “Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival,” Cancer Cell, vol. 25, pp. 719–734, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. D. R. Cox, “Regression models and life-tables,” Journal of the Royal Statistical Society Series B: Methodological, vol. 34, pp. 187–220, 1972. View at Google Scholar · View at MathSciNet
  28. A. Anjomshoaa, Y.-H. Lin, M. A. Black et al., “Reduced expression of a gene proliferation signature is associated with enhanced malignancy in colon cancer,” British Journal of Cancer, vol. 99, no. 6, pp. 966–973, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. A.-C. Haury, P. Gestraud, and J.-P. Vert, “The influence of feature selection methods on accuracy, stability and interpretability of molecular signatures,” PLoS ONE, vol. 6, no. 12, Article ID e28210, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Smit, H. C. J. Hoefsloot, and A. K. Smilde, “Statistical data processing in clinical proteomics,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 866, no. 1-2, pp. 77–88, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Simon, M. D. Radmacher, K. Dobbin, and L. M. McShane, “Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification,” Journal of the National Cancer Institute, vol. 95, no. 1, pp. 14–18, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. E. L. van Persijn van Meerten, H. Gelderblom, and J. L. Bloem, “RECIST revised: Implications for the radiologist. A review article on the modified RECIST guideline,” European Radiology, vol. 20, no. 6, pp. 1456–1467, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. R. Huang, W. Jiang, J. Yang et al., “A biotin label-based antibody array for high-content profiling of protein expression,” Cancer Genomics and Proteomics, vol. 7, no. 3, pp. 129–141, 2010. View at Google Scholar · View at Scopus
  34. Y. Saeys, I. Inza, and P. Larrañaga, “A review of feature selection techniques in bioinformatics,” Bioinformatics, vol. 23, no. 19, pp. 2507–2517, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Simon, “Supervised analysis when the number of candidate features (p) greatly exceeds the number of cases (n),” ACM SIGKDD Explorations Newsletter, vol. 5, no. 2, pp. 31–36, 2003. View at Publisher · View at Google Scholar
  36. B. Seliger and D. Quandt, “The expression, function, and clinical relevance of B7 family members in cancer,” Cancer Immunology, Immunotherapy, vol. 61, no. 8, pp. 1327–1341, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. L. Chen, P. McGowan, S. Ashe et al., “Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity,” Journal of Experimental Medicine, vol. 179, no. 2, pp. 523–532, 1994. View at Publisher · View at Google Scholar · View at Scopus
  38. L. Wang, Q. Ma, X. Chen, K. Guo, J. Li, and M. Zhang, “Clinical significance of B7-H1 and B7-1 expressions in pancreatic carcinoma,” World Journal of Surgery, vol. 34, no. 5, pp. 1059–1065, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. L. Wang, H. Liu, X. Chen, M. Zhang, K. Xie, and Q. Ma, “Immune sculpting of norepinephrine on MHC-I, B7-1, IDO and B7-H1 expression and regulation of proliferation and invasion in pancreatic carcinoma cells,” PLoS ONE, vol. 7, no. 9, Article ID e45491, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. J. LeCouter, J. Kowalski, J. Foster et al., “Identification of an angiogenic mitogen selective for endocrine gland endothelium,” Nature, vol. 412, no. 6850, pp. 877–884, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Balu, L. Pirtea, P. Gaje, A. M. Cimpean, and M. Raica, “The immunohistochemical expression of endocrine gland-derived-VEGF (EG-VEGF) as a prognostic marker in ovarian cancer,” Romanian Journal of Morphology and Embryology, vol. 53, no. 3, pp. 479–483, 2012. View at Google Scholar · View at Scopus
  42. H. Nagano, T. Goi, K. Koneri, Y. Hirono, K. Katayama, and A. Yamaguchi, “Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) expression in colorectal cancer,” Journal of Surgical Oncology, vol. 96, no. 7, pp. 605–610, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. D. Pasquali, V. Rossi, S. Staibano et al., “The endocrine-gland-derived vascular endothelial growth factor (EG-VEGF)/prokineticin 1 and 2 and receptor expression in human prostate: up-regulation of EG-VEGF/prokineticin 1 with malignancy,” Endocrinology, vol. 147, no. 9, pp. 4245–4251, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. Q. Li, B. Xu, L. Fu, and X. S. Hao, “Correlation of four vascular specific growth factors with carcinogenesis and portal vein tumor thrombus formation in human hepatocellular carcinoma,” Journal of Experimental and Clinical Cancer Research, vol. 25, no. 3, pp. 403–409, 2006. View at Google Scholar · View at Scopus
  45. X. Jiang, I. Abiatari, B. Kong et al., “Pancreatic islet and stellate cells are the main sources of endocrine gland-derived vascular endothelial growth factor/prokineticin-1 in pancreatic cancer,” Pancreatology, vol. 9, no. 1-2, pp. 165–172, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. E. S. W. Ngan, F. Y. L. Sit, K. Lee et al., “Implications of endocrine gland-derived vascular endothelial growth factor/prokineticin-1 signaling in human neuroblastoma progression,” Clinical Cancer Research, vol. 13, no. 3, pp. 868–875, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Brouillet, P. Hoffmann, J. J. Feige, and N. Alfaidy, “EG-VEGF: a key endocrine factor in placental development,” Trends in Endocrinology and Metabolism, vol. 23, no. 10, pp. 501–508, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. S. V. Kotenko, “IFN-λs,” Current Opinion in Immunology, vol. 23, no. 5, pp. 583–590, 2011. View at Publisher · View at Google Scholar
  49. S. G. Maher, F. Sheikh, A. J. Scarzello et al., “IFNα and IFNλ differ in their antiproliferative effects and duration of JAK/STAT signaling activity,” Cancer Biology and Therapy, vol. 7, no. 7, pp. 1109–1115, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. R. P. Donnelly and S. V. Kotenko, “Interferon-lambda: a new addition to an old family,” Journal of Interferon and Cytokine Research, vol. 30, no. 8, pp. 555–564, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. A. J. Novak, D. M. Grote, S. C. Ziesmer, V. Rajkumar, S. E. Doyle, and S. M. Ansell, “A role for IFN-λ1 in multiple myeloma B cell growth,” Leukemia, vol. 22, no. 12, pp. 2240–2246, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. D. L. Falls, “Neuregulins: functions, forms, and signaling strategies,” Experimental Cell Research, vol. 284, no. 1, pp. 14–30, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. N. V. L. Hayes and W. J. Gullick, “The neuregulin family of genes and their multiple splice variants in breast cancer,” Journal of Mammary Gland Biology and Neoplasia, vol. 13, no. 2, pp. 205–214, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. L. Yen, X.-L. You, A.-E. Al Moustafa et al., “Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis,” Oncogene, vol. 19, no. 31, pp. 3460–3469, 2000. View at Publisher · View at Google Scholar · View at Scopus
  55. C. Stove and M. Bracke, “Roles for neuregulins in human cancer,” Clinical and Experimental Metastasis, vol. 21, no. 8, pp. 665–684, 2005. View at Publisher · View at Google Scholar · View at Scopus
  56. A. Kolb, J. Kleeff, N. Arnold et al., “Expression and differential signaling of heregulins in pancreatic cancer cells,” International Journal of Cancer, vol. 120, no. 3, pp. 514–523, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. J. S. Liles, J. P. Arnoletti, C. W. D. Tzeng et al., “ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma,” Cancer Biology and Therapy, vol. 10, no. 6, pp. 555–563, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. J. S. Liles, J. P. Arnoletti, A. V. Kossenkov et al., “Targeting ErbB3-mediated stromal-epithelial interactions in pancreatic ductal adenocarcinoma,” British Journal of Cancer, vol. 105, no. 4, pp. 523–533, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. A. Bronckaers, F. Gago, J. Balzarini, and S. Liekens, “The dual role of thymidine phosphorylase in cancer development and chemotherapy,” Medicinal Research Reviews, vol. 29, no. 6, pp. 903–953, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. S. Liekens, A. Bronckaers, M.-J. Pérez-Pérez, and J. Balzarini, “Targeting platelet-derived endothelial cell growth factor/thymidine phosphorylase for cancer therapy,” Biochemical Pharmacology, vol. 74, no. 11, pp. 1555–1567, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. L. Wang, X. Huang, Y. Chen, X. Jin, Q. Li, and T. N. Yi, “Prognostic value of TP/PD-ECGF and thrombocytosis in gastric carcinoma,” European Journal of Surgical Oncology, vol. 38, no. 7, pp. 568–573, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. G. P. Dunn, C. M. Koebel, and R. D. Schreiber, “Interferons, immunity and cancer immunoediting,” Nature Reviews Immunology, vol. 6, no. 11, pp. 836–848, 2006. View at Publisher · View at Google Scholar · View at Scopus
  63. Z. V. Fong and J. M. Winter, “Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive,” Cancer Journal, vol. 18, no. 6, pp. 530–538, 2012. View at Publisher · View at Google Scholar · View at Scopus